Clinical trials: Experimental, completed
Advanced Solid Tumor
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
The study was conducted in two periods, Period 1 (mass balance) and Period 2 (extension). The purpose of Period 1 of this study was to provide a quantitative characterization of the mass balance, rates and routes of elimination…
- Trial name
- NCT05246111
- Testing
- [14C]Berzosertib, Berzosertib, Topotecan
- Where
- 2 sites in Hungary
- Volunteers
- 6 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
HIV/AIDS, Health Behaviors
Expanding HIV Testing Among Uganda Adults Who Utilize Traditional Healers
HIV antiretroviral therapy has the potential to dramatically decrease HIV transmission worldwide1; yet, a barrier to ending the AIDS epidemic in low-resource settings is the fact that healthcare is largely provided by traditional…
- Trial name
- NCT03718871
- Testing
- HIV testing at traditional healer practices
- Where
- Uganda
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Weill Medical College of Cornell University
ST-segment Elevation Myocardial Infarction
Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients
Evaluate the efficacy, Safety and Pharmacokinetics of Intravenous single injection LC28-0126 immediately before PCI (Percutaneous Coronary Intervention) in Patients with STEMI (ST-segment Elevation Myocardial Infarction)
- Trial name
- NCT02070471
- Testing
- LC28-0126 Dose A, LC28-0126 Dose B, LC28-0126 Dose C
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- LG Life Sciences
Sickle Cell Anemia
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia
Hydroxyurea (HU) is approved by the United States Food and Drug Administration (FDA) to treat adults with sickle cell anemia. Hydroxyurea has also been tested and used with children with sickle cell anemia.
- Trial name
- HU (NCT01506544)
- Testing
- Hydroxyurea
- Where
- 6 sites in United States
- Volunteers
- 39 people
- Sponsor
- Children's Mercy Hospital Kansas City
Drug-resistant Epilepsy
Electrophysiologic Studies of Cognition in Epilepsy Patients
Interoception, or sensation from inside the body, is involved in a variety of clinical symptoms, such as tics, compulsions and negative mood.
- Trial name
- NCT05769634
- Testing
- Stereoelectroencephalography
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Psoriatic Arthritis
Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis
This study was to provide 24 - 52 week efficacy, safety and tolerability data to support the registration of the secukinumab (AIN457) prefilled syringe (PFS) for subcutaneous self administration in subjects with active PsA…
- Trial name
- FUTURE 2 (NCT01752634)
- Testing
- Secukinumab (AIN457)
- Where
- 76 sites in United States, Australia and 9 more
- Volunteers
- 397 people
- Sponsor
- Novartis Pharmaceuticals
Arrhythmia
Perclose Multi-Access Duplex Ultrasound (DUS) Study
The aim of this prospective, single-arm, United States (US) multi-center, descriptive clinical study is to evaluate the safety of multiple access site closure in a single vein with the SMC System by scheduled DUS at discharge and…
- Trial name
- NCT04904809
- Testing
- Perclose ProGlide SMC System and/or Perclose ProStyle SMCR System
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Abbott Medical Devices
Healthy
A Study To Observe Safety And Blood Concentrations Of PF-06649751 During And Following The Oral Administration Of Multiple Doses Of PF-06649751 In Healthy Adult Western and Japanese Volunteers
This study is designed to evaluate the safety and plasma concentrations of PF-06649751 in healthy volunteers following one or two times daily oral dosing of PF-06649751 for 14 days (Cohorts 1 - 4), 21 days (Cohort 5), or 28 days…
- Trial name
- NCT02066909
- Testing
- 0.15 mg PF-06649751, 0.5 mg PF-06649751, 1.5 mg PF-06649751
- Where
- United States
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Pfizer
Cervical Cancer Screening, Breast Cancer Screening
Social Media-Based Education on Cancer Screening Awareness in Women: A Randomized Controlled Trial
This randomized controlled study evaluated a social media-based educational program for women who had not previously participated in breast, cervical, or colorectal cancer screening.
- Conditions
- Cervical Cancer Screening, Breast Cancer Screening, Colorectal Cancer Screening, Digital Health Literacy
- Trial name
- NCT06939699
- Testing
- Social Media-Based Education, Standard Online Education
- Where
- Turkey (Türkiye)
- Volunteers
- 132 people, healthy volunteers welcome
- Sponsor
- Emine Ergin
Thyroid Diseases, Surgical Injury
Feasibility of Neostigmine for Intraoperative Neuromonitoring in Thyroid Surgery
For successful intraoperative neuromonitoring (IONM), adequate reversal of neuromuscular blocking agent is a prerequisite in thyroid surgery with .
- Conditions
- Thyroid Diseases, Surgical Injury, Nerve Monitoring
- Trial name
- NCT04873531
- Testing
- Neostigmine, Normal saline
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Seoul National University Hospital
Metastatic Renal Cell Carcinoma
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
This study is being done with patients with advanced kidney cancer (also called renal cell carcinoma or RCC). This is a research study involving the use of the drug Nivolumab (also known as Opdivo®).
- Trial name
- NCT03126331
- Testing
- Nivolumab, Ipilimumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Case Comprehensive Cancer Center
Weight Loss, Pediatric Obesity
Dyad Plus Effectiveness/Feasibility
The purpose of this research is to determine the effectiveness of a coordinated program (Dyad Plus) that would help to facilitate self-monitoring, positive communication, joint problem solving, and social support to increase…
- Conditions
- Weight Loss, Pediatric Obesity, Overweight Adolescents, Parent-Child Relations
- Trial name
- NCT04036331
- Testing
- Brenner FIT Standard, By Design Essentials, Dyad Plus
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Cancer
Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid Tumors
This study is to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD) and anti-tumor activity of AK105 as a single agent in adult subjects with advanced solid tumor malignancies.
- Trial name
- NCT03352531
- Testing
- AK-105
- Where
- 5 sites in Australia
- Volunteers
- 99 people
- Sponsor
- Akesobio Australia Pty Ltd
Ineffective Esophageal Motility, Dysphagia
Treatment of Dysphagia and Ineffective Esophageal Motility With Prucalopride: A Pilot Study
This study will test prucalopride (a prokinetic drug currently approved by Health Canada for treatment of constipation) as a treatment for Ineffective Esophageal Motility (IEM).
- Trial name
- IEMPru (NCT03244553)
- Testing
- Prucalopride
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- University of Calgary
Dementia (Diagnosis)
DemTool - Supporting Life With Dementia
This study will investigate the effects of a Danish psychosocial intervention, specifically the DemTool - supporting life with dementia, on quality of life and caregiver strain in family caregivers of people with dementia.
- Trial name
- DemTool (NCT07355829)
- Testing
- Life with dementia in the community - Support group for family caregivers, Life with dementia in the community - Group course, Life with dementia in a care home- Group course
- Where
- Denmark
- Volunteers
- 272 people
- Sponsor
- Danish Dementia Research Centre
Healthy Subjects
Homeopathic Drug Proving Trial
The main aim of the study is to determine whether a homeopathic drug in the potency C12 provokes more characteristic homeopathic proving symptoms after three weeks compared to a placebo in healthy volunteers.
- Trial name
- HAMSV (NCT01061229)
- Testing
- Homeopathic drug C12
- Where
- Germany
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
This phase I/II trial studies the side effects and best dose of auranofin when given together with sirolimus and to see how well it works in treating patients with lung cancer that has spread or other places in the body and…
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Carcinoma, Recurrent Small Cell Lung Carcinoma
- Trial name
- NCT01737502
- Testing
- Auranofin, Sirolimus, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Mayo Clinic
Functional Neurological Disorder
Body Signal Integration Training: A Case Series
The goal of this clinical trial is to learn about an intervention package in individuals with Functional Neurological Disorder (FND).
- Trial name
- NCT05941702
- Testing
- Body Signal Integration Training
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- University of Manchester
Schizophrenia, Bipolar Disorder
Real-Time Mobile Cognitive Behavioral Intervention for Serious Mental Illness
The purpose of this study is to evaluate the effectiveness of a mobile real-time cognitive behavioral intervention for serious mental illness (SMI) and to identify the facilitators, barriers, and costs of implementation.
- Trial name
- NCT02035202
- Testing
- CBT2go, Smartphone
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- University of California, San Diego
Heart Catheterization
Randomized, Open Label Study of Dabigatran Etexilate in Elective Percutaneous Coronary Intervention
To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide…
- Trial name
- NCT00818753
- Testing
- dabigatran 110 mg, dabigatran 150 mg, unfractionated heparin
- Where
- 4 sites in Netherlands
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
The first 5,000 results can be paged through. Add a filter or change the sort order to reach the rest.